Postinjection Endophthalmitis in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT)
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Objective To describe the incidence and outcomes of endophthalmitis after intravitreal injections of anti-VEGF agents in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT) and to assess the effect of use of prophylactic topical antimicrobials on incidence. Design Cohort study within a randomized clinical trial. Participants Patients enrolled in CATT. Methods Patients with neovascular age-related macular degeneration received intravitreal injections of ranibizumab or bevacizumab under one of three dosing regimens. The study protocol specified pre-injection preparation to include use of a sterile lid speculum and povidone iodine (5%). Use of pre-and post-injection antibiotics was at the discretion of the treating ophthalmologist. Patients were followed monthly for two years. Main Outcome Measures Development of endophthalmitis and visual acuity. Results Endophthalmitis developed after 11 of 18,509 injections (1 per 1,700; 0.06%; 95% Confidence Interval (0.03%, 0.11%)), and among 11 of 1185 patients (0.93%; 95% Confidence Interval (0.52, 1.66)). Incidence of endophthalmitis was 0.15% among injections with no antibiotic use, 0.08% among injections with pre-injection antibiotics only, 0.06% among injections with post-injection antibiotics only, and 0.04% among injections with pre-and post-injection antibiotics (p=0.20). All eyes were treated with intravitreal antibiotics and 4 had vitrectomy. Among the 11 affected eyes, the final study visual acuity was 20/40 or better in 4 (36%) eyes, 20/50-20/80 in 2 (18%) eyes, 20/100-20/160 in 3 (27%) , and <20/800 in 2 (18%) eyes. The final visual acuity was within 2 lines of the visual acuity before endophthalmitis in 5 (45%) eyes. Conclusion Rates of endophthalmitis were low and similar to those in other large scale studies. Use of topical antibiotics either before or after injection does not appear to reduce the risk for endophthalmitis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Martin, D. F., Maguire, M. G., Fine, S. L., Ying, G.-S., Jaffe, G. J., Grunwald, J. E., Toth, C., Redford, M., & Ferris, F. L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.03.053 · Cited by 1,715
Self-citationWu, L., Martínez-Castellanos, M. A., Quiroz-Mercado, H., Arevalo, J. F., Berrocal, M. H., Farah, M. E., Maia, M., Roca, J. A., Rodriguez, F. J., & for the Pan American Collaborative Retina Group (PACORES) (2007) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-007-0660-z · Cited by 456 · cited 1×
“negative, but negative culture results have been reported in several studies of endophthalmitis when it was highly likely that an infectious organism was present.(21,35) Instead, what was unique in these 3 cases was that the inflammation either completely resolved with topical steroids alone and no antibiotic (1 case…”
Cited by
Age-related macular degeneration
Mitchell, P., Liew, G., Gopinath, B., & Wong, T. Y. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31550-2 · Cited by 1,511
Age-related macular degeneration
Fleckenstein, M., Keenan, T. D. L., Guymer, R. H., Chakravarthy, U., Schmitz-Valckenberg, S., Klaver, C. C., Wong, W. T., & Chew, E. Y. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00265-2 · Cited by 978
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration
Solomon, S. D., Lindsley, K., Vedula, S. S., Krzystolik, M. G., & Hawkins, B. S. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005139.pub3 · Cited by 520
2018 Update on Intravitreal Injections: Euretina Expert Consensus Recommendations
Grzybowski, A., Told, R., Sacu, S., Bandello, F., Moisseiev, E., Loewenstein, A., Schmidt-Erfurth, U., & on behalf of the Euretina Board (2018) · Ophthalmologica · doi:10.1159/000486145 · Cited by 297
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration
Solomon, S. D., Lindsley, K., Vedula, S. S., Krzystolik, M. G., & Hawkins, B. S. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005139.pub4 · Cited by 271
Metadata
- Authors
- Meredith, T. A., McCannel, C. A., Barr, C., Doft, B. H., Peskin, E., Maguire, M. G., Martin, D. F., & Prenner, J. L.
- Venue
- Ophthalmology
- Publisher
- Elsevier BV
- Published
- 2015-04
- Volume
- 122
- Issue
- 4
- Pages
- 817-821
- ISSN
- 0161-6420 (ISSN-L)
- OpenAlex
- W2009115140
- Cited by
- 84
- References
- 5
- FWCI
- 11.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Postinjection Endophthalmitis in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). https://app.cochat.ai/papers/10.1016/j.ophtha.2014.10.027
- The paper
- Meredith, T. A., McCannel, C. A., Barr, C., Doft, B. H., Peskin, E., Maguire, M. G., Martin, D. F., & Prenner, J. L. (2015). Postinjection Endophthalmitis in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Ophthalmology. https://doi.org/10.1016/j.ophtha.2014.10.027
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.